 |
 Video: What is a Stock Split?
|
|
|
| Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line. According to our Fate Therapeutics stock split history records, Fate Therapeutics has had 0 splits. | |
|
Fate Therapeutics (FATE) has 0 splits in our Fate Therapeutics stock split history database.
Looking at the Fate Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Fate Therapeutics shares, starting with a $10,000 purchase of FATE, presented on a split-history-adjusted basis factoring in the complete Fate Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
04/17/2024 |
|
| Start price/share: |
$7.11 |
|
| End price/share: |
$5.27 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-25.88% |
|
| Average Annual Total Return: |
-2.95% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$7,413.56 |
|
| Years: |
9.99 |
|
|
|
|
|
